Entera Bio Ltd. (ENTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $2.95: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and... Read more
Sell if holding. Engine safety override at $2.95: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 4.4/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Entera Bio Ltd.
About Entera Bio Ltd.
Entera Bio's clinical pipeline centers on EB613, an oral once-daily PTH(1-34) tablet for postmenopausal osteoporosis advancing toward a roughly 750-patient Phase 3 study after the FDA's December 2025 qualification of total hip bone mineral density as a surrogate fracture endpoint. The company also develops EB612 for hypoparathyroidism and, with OPKO Biologics, oral GLP-1/Glucagon (EB618) and GLP-2 programs, while reporting no product revenue, an $11.4 million 2025 net loss, and a $125.4 million accumulated deficit.
Entera generates no product revenue today; its business model instead rests on advancing its N-Tab oral-delivery platform, designed to stabilize large hydrophilic peptides against gastrointestinal enzymatic degradation and promote their absorption into the bloodstream, and monetizing that platform through wholly owned and partnered pipeline assets. Entera retains global rights to EB613, its lead osteoporosis candidate, while its hypoparathyroidism, oral GLP-1/Glucagon, and GLP-2 programs run through collaboration and license agreements with OPKO Biologics: the companies split EB612 rights 50/50, and Entera and OPKO split OXM (EB618) proceeds and development costs 40/60, respectively, falling to a 15/85 split if Entera exercises its post-Phase-1 opt-out. The FDA has granted EB612 orphan drug designation, and Entera's most advanced clinical dataset — a Phase 2, 6-month, 161-patient placebo-controlled trial of EB613 — met all biomarker and bone-density endpoints, with results published in the Journal of Bone and Mineral Research in April 2024.
Show full overview
EB613 functions as a binary bet for Entera: the 10-K states existing cash would fund operations only through the middle of the third quarter of 2026, explicitly excluding the costs of starting the Phase 3 osteoporosis trial, and management flagged substantial doubt about the company's ability to continue as a going concern. In July 2026, the company disclosed via Form 8-K a $275.0 million private placement priced at $2.04 per share, addressing that funding gap; because EB613 is Entera's most advanced program and the one to which it retains full global rights (unlike EB612, EB618, and GLP-2, which are shared with OPKO), any delay in Phase 3 execution or an unfavorable readout would disproportionately weigh on the company relative to its partnered assets.
From Entera Bio Ltd.'s most recent 10-K filing, extracted August 30, 2026.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $2.95: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $2.73. Score 4.4/10, moderate confidence.
Take-profit target: $3.49 (+18.7% upside). Prior stop was $2.73. Stop-loss: $2.73.
DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $2.94 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.6 < 4.0).
Entera Bio Ltd. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 5.0/10. Verdict: Sell.
7 analysts cover ENTX with a consensus score of 4.1/5. Average price target: $9.
What does Entera Bio Ltd. do?Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement...
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.